Join the Oncology Voice Network. Join for Free
Why MSLs Need a Personal Board of Directors
Medical Science Liaisons personal board of directors MSL career development mentorship in medical affairs Medical Affairs Executive Coach

Why MSLs Need a Personal Board of Directors


Share This Article


Summary

In this episode, Tom Caravela welcomes Marieke Jonkman to discuss the concept of creating a personal board of directors for Medical Science Liaisons (MSLs). Marieke shares her career journey and emphasizes the importance of selecting and approaching the right individuals to form a supportive board. The conversation covers the roles and expectations of board members in an MSL's development, highlighting the reciprocal nature of mentorship and the involvement of managers. Marieke also provides insights on maintaining and nurturing these crucial relationships. The episode concludes with closing remarks and a call to action for listeners to engage with the MSL Talk community.

My guest today is Marieke Jonkman, Medical Affairs Executive Coach at the Medical Affairs Institute and we discuss why MSLs should have their own personal board of directors

Marieke discusses…

πŸ‘‰ What would a personal board of directors look like
πŸ‘‰ How to go about finding people for your PBD
πŸ‘‰ Who you should ask to be on your board
πŸ‘‰ How to approach a potential board member

Click for Source
Medical Science Liaisons, personal board of directors, MSL career development, mentorship in medical affairs, Medical Affairs Executive Coach

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN